_1777294237270_124456903.png&w=64&q=75){kind=small}
Weight loss product rivals others
The new drug "Cagrisima" proves to be effective in treating obesity and weight loss. Advanced clinical trials have shown promising results that surpass some doses of "Tirzepatide." Patients with type 2 diabetes lost 12.4% of their body weight over 60 weeks using it, compared to 9% among users of a 5 mg dose of "Tirzepatide." Another study recorded approximately a 21% weight loss over 68 weeks in patients suffering from obesity or overweight. The medication is administered via a weekly injection and targets appetite and satiety, combining the effects of "Semaglutide" and "Kagrelintaide." Its side effects include nausea, vomiting, diarrhea, and constipation. It has not yet received approval from the U.S. Food and Drug Administration, although the company has submitted an application to bring it to market upon approval.
Notice: This Is an AI-Generated Summary
Comments (0)